Parkinson’s disease: Servier and Oncodesign announce the selection of a preclinical candidate
Initiated in March 2019, this Research and Development partnership is focused on the identification of LRRK2 kinase inhibitors derived from Oncodesign’s proprietary Nanocyclix® platform and their potential to act as therapeutic agents against Parkinson’s disease, drawing on Servier and Oncodesign’s complementary expertise in the field of neurodegenerative disease and kinase inhibitors.
Streamline the choice of therapeutic direction for your projects by qualifying the potential of your molecules and your in vitro targets.
T.O.T. qualifies the therapeutic potential of a target or molecule in vitro: cell imaging, new phenotype tests on 3D tissue cultures, molecular characterization of signaling pathways, etc.
Linked to our patient-derived PDX experimental models and the analysis of associated clinical data, T.O.T. Allows you to experimentally reconstruct a patient cohort in order to confirm or adjust a preclinical and clinical development strategy.